David Ledbetter is chief clinical officer of Dascena, a personalized medicine company.
David Ledbetter
Chief clinical officer
Dascena
From this contributor
There are no autism-specific genes, just brain genes
There is not yet a single example of a gene that, when mutated, increases the likelihood of autism but not of other neurodevelopmental conditions, including intellectual disability.
There are no autism-specific genes, just brain genes
By
David Ledbetter, Scott Myers
23 March 2021 | 5 min read
Developmental disorders should be viewed as continuum
Intellectual disability, autism, epilepsy and schizophrenia should be considered part of a spectrum of developmental brain dysfunction, says David Ledbetter.
Developmental disorders should be viewed as continuum
By
David Ledbetter
6 May 2013 | 3 min read
Explore more from The Transmitter
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
By
Chand Chandrasekaran
20 April 2026 | 6 min read
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
By
Angie Voyles Askham
17 April 2026 | 8 min read
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
By
Charles Q. Choi
16 April 2026 | 4 min read